Business Wire

VeriSilicon and Innobase Collaboratively Launched Second-Generation Yunbao Series 5G RedCap/4G LTE Dual-Mode Modem IP

Share

Advancing cellular mobile communication technology innovation and accelerating the lightweight 5G application adoption

VeriSilicon (688521.SH) today announced the joint launch of the second-generation Yunbao series 5G RedCap/4G LTE dual-mode modem IP, Yunbao 2, in collaboration with Innobase, a wireless communication technology and chip provider. This new modem IP has successfully completed production validation.

The newly launched modem IP integrates and reuses 4G and 5G hardware accelerators, delivering industry-leading performance in terms of area and power consumption. This IP complies with the 3GPP 5G Rel-17 standard and supports both 5G RedCap and 4G LTE FDD/TDD, achieving uplink and downlink transmission rates of 170 Mbps and 120 Mbps, respectively. It also supports multi-SIM standby and features key 5G capabilities such as Ultra-Reliable Low Latency Communication (URLLC), 5G LAN, and network slicing. Furthermore, chips developed using the Yunbao 2 modem IP can be paired with Innobase’s production-validated high-performance dual-mode RF chips, enabling seamless product-level integration and significantly accelerating the commercialization process for customers.

Under the guidance and organization of the IMT-2020 (5G) Promotion Group, the Yunbao series has successfully completed 5G RedCap terminal equipment and field performance testing with Nokia Shanghai Bell and ZTE. Additionally, it has completed interoperation tests between 5G RedCap terminals and base stations in collaboration with partners. These tests were conducted strictly adhering to the standards set by the Promotion Group, covering the full range of 5G RedCap terminal functionalities and performance metrics. The results thoroughly validated the overall capabilities of the Yunbao series, as well as its seamless interoperability with multiple network equipment vendors.

“The commercialization of RedCap in China has entered a rapid growth phase. As a new 5G variant defined under the 3GPP Rel-17 standard, RedCap features low cost, low latency, private network, and efficient spectrum utilization, making it an ideal solution for wearable devices, industrial IoT, and mass-market smartphones,” said Lu Wenbo, Senior Vice President of Innobase. “Innobase has introduced a variety of mass-production-ready products, including 5G IoT modules, MiFi devices, and mass-market 5G smartphones, which have successfully validated the Yunbao series IP at the product level. In the future, Innobase will leverage its extensive expertise in cellular communication technologies to develop the Yunbao X series featuring ultra-low-cost and ultra-low-power designs, to address the needs of consumer electronics and IoT applications. With the RedCap market rapidly evolving, we are excited to collaborate with VeriSilicon to deliver more advanced 5G multi-mode modem IP solutions to our customers.”

“The cost and performance of 5G RedCap chips are comparable to those of 4G, further expanding the boundaries of existing 4G application scenarios,” said Wiseway Wang, Executive Vice President, General Manager of Custom Silicon Platform Division of VeriSilicon. “Through our collaboration with Innobase, VeriSilicon is able to offer production-validated 4G/5G RedCap dual-mode IPs, further strengthening our existing IP ecosystem. VeriSilicon remains committed to driving innovation in low-power, high-performance wireless communication technologies, providing comprehensive wireless communication solutions, including RF, baseband, and protocol stacks, for IoT applications. Looking ahead, VeriSilicon will continue working closely with industry partners to build a global cellular communication ecosystem and contribute to an intelligent, connected future.”

About Innobase

Innobase is a leading fabless chip design company for cellular mobile communications. It designs chipset of 4G/5G and future 6G, including Baseband, RF, and PMIC for mobile terminals. Its dual mode chipset of 4G LTE/5G RedCap is commercialized with customers including telecom operators, IoT module makers, and mobile phone IDHs/ODMs. For more information, please visit: www.innobase.com.cn

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121582002/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press release

The disruption generated by AI enables the acceleration and industrialisation of the creation of internal solutions and start-ups through centres of excellence in Chicago, Madrid and Tbilisi.This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the depl

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press release

Deseyne® (vifilcon C) Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia with Extended Depth of Focus (EDOF) Delivers Continuous Vision at All Distances—Redefining Presbyopia Correction The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifoc

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release

Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve

Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release

Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye